English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18055/20253 (89%)
Visitors : 25100763      Online Users : 550
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/28523


    Title: B-Type Natriuretic Peptide Inhibits Angiotensin II-Induced Proliferation and Migration of Pulmonary Arterial Smooth Muscle Cells
    Authors: Hsu, Jong-Hau
    Liou, Shu-Fen
    Yang, San-Nan
    Wu, Bin-Nan
    Dai, Zen-Kong
    Chen, Ing-Jun
    Yeh, Jwu-Lai
    Wu, Jiunn-Ren
    Contributors: 藥學系
    Keywords: pulmonary vascular remodeling
    reactive oxygen species
    cGMP
    Date: 2014-08
    Issue Date: 2015-05-06 21:19:21 (UTC+8)
    Publisher: Wiley-Blackwell
    Abstract: Pulmonary vascular remodeling, characterized by disordered proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs), is a pathognomonic feature of pulmonary arterial hypertension. Thus, pharmacologic strategy targeting on anti-proliferation and anti-migration of PASMCs may have therapeutic implications for PAH. Here we investigated the effects and underlying mechanisms of B-type natriuretic peptide (BNP) on angiotensin II (Ang II)-induced proliferation and migration of PASMCs. Proliferation and migration of PASMCs cultured from Wistar rats were induced by Ang II, with or without BNP treatment. In addition, potential underlying mechanisms including cell cycle progression, Ca2+ overload, reactive oxygen species (ROS) production, signal transduction of MAPK and Akt, and the cGMP/PKG pathway were examined. We found that BNP inhibited Ang II-induced PASMCs proliferation and migration dose dependently. BNP could also arrest the cell cycle progression in the G(0)/G(1)-phase. In addition, BNP attenuated intracellular calcium overload caused by Ang II. Moreover, Ang II-induced ROS production was mitigated by BNP, with associated down-regulation of NAD(P)H oxidase 1 (Nox1) and reduced mitochondrial ROS production. Finally, Ang II-activated MAPKs and Akt were also counteracted by BNP. Of note, all these effects of BNP were abolished by a PKG inhibitor (Rp-8-Br-PET-cGMPS). In conclusion, BNP inhibits Ang II-induced PASMCs proliferation and migration. These effects are potentially mediated by decreased calcium influx, reduced ROS production by Nox1 and mitochondria, and down-regulation of MAPK and Akt signal transduction, through the cGMP/PKG pathway. Therefore, this study implicates that BNP may have a therapeutic role in pulmonary vascular remodeling. (C) 2013 Wiley Periodicals, Inc.
    Relation: Pediatric Pulmonology, v.49 n.8, pp.734-744
    Appears in Collections:[Dept. of Pharmacy] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML1708View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback